TG Therapeutics: Positive Interim Data in Lymphoma Phase 2b at ASCO

Overall response rate (ORR) of 52% (N=42), with complete response (CR) rate of 19%, by central independent review committee (IRC) 

Umbralisib was well tolerated with a safety profile that appeared to be maintained with prolonged exposure

TG Therapeutics, Inc. (NASDAQ: TGTX) today presented positive interim data from the ongoing single-arm marginal zone lymphoma (MZL) cohort of its Phase 2b UNITY-NHL trial currently evaluating umbralisib as a single agent in patients with relapsed/refractory MZL. Umbralisib is an investigational, oral, once-daily PI3K delta inhibitor with unique inhibition of CK1 epsilon and is currently under development for the treatment of non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL).

The interim data were presented today in an oral session during the 55th American Society of Clinical Oncology (ASCO) Annual Meeting. The slides presented are available on the Company’s corporate website at www.tgtherapeutics.com/publications.cfm.

https://www.globenewswire.com/news-release/2019/06/04/1864292/0/en/TG-Therapeutics-Presents-Positive-Interim-Data-from-UNITY-NHL-Phase-2b-Trial-Evaluating-Umbralisib-Monotherapy-in-Patients-with-Marginal-Zone-Lymphoma-at-the-55th-American-Society-.html